Related Experiment Videos
Idarubicin: an anthracycline antineoplastic agent
1College of Pharmacy and Allied Health Professions, Northeastern University, Boston, MA 02115.
Clinical Pharmacy
|February 1, 1992
Summary
Idarubicin, a daunorubicin analogue, is effective for acute nonlymphocytic leukemia and shows promise for other cancers. It offers oral bioavailability and potentially less cardiotoxicity compared to other anthracyclines.
Area of Science:
- Oncology
- Pharmacology
Background:
- Idarubicin is an anthracycline antibiotic used in cancer chemotherapy.
- It is a structural analogue of daunorubicin.
Purpose of the Study:
- To review the mechanism of action, pharmacokinetics, activity, adverse effects, and administration of idarubicin.
- To compare idarubicin's efficacy and safety with other anthracyclines.
Main Methods:
- Review of existing literature on idarubicin.
- Analysis of clinical trial data comparing idarubicin-based regimens with daunorubicin-based regimens.
Main Results:
- Idarubicin is approved for adult acute nonlymphocytic leukemia (ANLL) and is at least as effective as daunorubicin.
- Idarubicin-cytarabine regimens show greater activity and longer survival than daunorubicin-cytarabine regimens in ANLL.
- Idarubicin demonstrates activity in acute lymphocytic leukemia, lymphomas, and breast cancer.
- Adverse effects are similar to other anthracyclines, with potentially less cardiotoxicity.
- Idarubicin has significant oral bioavailability (28%), with an oral dosage form under investigation.
Conclusions:
- Idarubicin is an effective agent for ANLL management.
- It is potentially more potent and less cardiotoxic than daunorubicin or doxorubicin.
- Further research is needed to define the maximum cumulative dose to prevent cardiotoxicity.